Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Toronto Stock Exchange  >  Cardiome Pharma Corp    COM   CA14159U3010

 SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Toronto Stock Exchange
02/15/2017 02/16/2017 02/17/2017 02/21/2017 02/22/2017 Date
3.9 3.94 3.94 3.91 3.96 Last
5900 12075 10800 1745 8110 Volume
+0.78% +1.03% 0.00% -0.76% +1.28% Change
Financials ( CAD)
Sales 2016 32,5 M
EBIT 2016 -19,3 M
Net income 2016 -25,6 M
Debt 2016 -
Yield 2016 -
Sales 2017 41,0 M
EBIT 2017 -9,21 M
Net income 2017 -15,2 M
Debt 2017 -
Yield 2017 -
P/E ratio 2016 -
P/E ratio 2017
Capi. / Sales2016 3,84x
Capi. / Sales2017 3,05x
Capitalization 125 M
More Financials
Company
Cardiome Pharma Corp. is a pharmaceutical company engages in provision of development and commercialization of medical products.It focuses on cardiovascular therapies that will improve the quality of life and health of patients suffering from heart disease.It offers the Brinavess and Aggrastat... 
Sector
Pharmaceuticals
Calendar
03/16Earnings Release
More about the company
Surperformance© ratings of Cardiome Pharma Corp
Trading Rating : Investor Rating :
More Ratings
Latest news on CARDIOME PHARMA CORP
2016 CARDIOME PHARMA : Announces Commercial Launch of XYDALBA(TM) (dalbavancin) in Ge..
2016 CARDIOME PHARMA : Announces Commercial Launch of Xydalba(TM) (dalbavancin) in th..
2016 CARDIOME PHARMA : Advances Toward the UK XYDALBA(TM) (dalbavancin) Launch
2016 CARDIOME PHARMA : Reports Third Quarter 2016 Financial Results
2016 CARDIOME PHARMA : to Reschedule Release of Third Quarter 2016 Financial Results
2016 CARDIOME PHARMA : to Hold Third Quarter 2016 Financial Results Conference Call o..
2016 CARDIOME PHARMA : Announces Initiation of Commercial Operations in Canada, Eh
2016 CARDIOME PHARMA : Announces Recent Insider Purchases
2016 CARDIOME PHARMA : Reports Second Quarter 2016 Financial Results
2016 CARDIOME PHARMA : Announces XYDALBA(TM) Single Dose Infusion Approval by Europea..
More news
Sector news : Biopharmaceuticals
02/22 Genmab and J&J's cancer drug set for blockbuster sales this year
02/22DJBAYER : Details Financing Plan for Monsanto Deal
02/22 EU regulators set to clear Dow, DuPont deal - sources
02/22 Covestro parent Bayer non-committal on any sale to industry peer
02/22DJBAYER : CEO Confident Monsanto Purchase Will Be Approved by End of Year -- Updat..
More sector news : Biopharmaceuticals
News from SeekingAlpha
2016 Recent analyst action
2016 Cardiome Pharma's (CRME) CEO Dr. Bill Hunter on Q3 2016 Results - Earnings Ca..
2016 Cardiome Pharma beats by $0.01, misses on revenue
2016 Notable earnings before Monday?s open
2016 Cardiome Pharma's (CRME) CEO Bill Hunter on Q2 2016 Results - Earnings Call T..
Advertisement
Chart CARDIOME PHARMA CORP
Duration : Period :
Cardiome Pharma Corp Technical Analysis Chart | COM | CA14159U3010 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Average target price 11,3  CAD
Spread / Average Target 189%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
William L. Hunter President, Chief Executive Officer & Director
William James O'Shea Chairman
Sheila M. Grant Chief Operating Officer
Jennifer Archibald Chief Financial Officer
Richard M. Glickman Lead Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
CARDIOME PHARMA CORP-1.26%95
BIOGEN INC9.78%61 957
CSL LIMITED19.31%41 752
ALEXION PHARMACEUTICAL..6.16%29 175
BIOMARIN PHARMACEUTICA..8.93%15 520
GRIFOLS SA11.89%14 042
More Results